**Psoriasis Resources and Associations**

|  |  |
| --- | --- |
| Resource | Address |
| Bakshi H, Nagpal M, Singh M, Dhingra GA, Aggarwal G. Treatment of psoriasis: A comprehensive review of entire therapies. *Curr Drug Saf*. 2020;15(2):82-104. doi:10.2174/1574886315666200128095958 | <https://pubmed.ncbi.nlm.nih.gov/31994468/> |
| Boehncke W, Brembilla N. Unmet needs in the field of psoriasis: Pathogenesis and treatment. *Clin Rev Allergy Immunol.* 2018;55(3):295-311. doi:10.1007/s12016-017-8634-3 | <https://pubmed.ncbi.nlm.nih.gov/28780731/> |
| Branisteanu DE, Cojocaru C, Diaconu R, et al. Update on the etiopathogenesis of psoriasis (Review). *Exp Ther Med*. 2022;23(3):201. doi:10.3892/etm.2022.11124 | <https://pubmed.ncbi.nlm.nih.gov/35126704/> |
| Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: A narrative review. *Front Immunol*. 2022;13:880201. doi:10.3389/fimmu.2022.880201 | <https://pubmed.ncbi.nlm.nih.gov/35757712/> |
| Ceccarelli M, Rullo E, Berretta M, et al. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. *Dermatol Ther.* 2021;34(1):e14660. doi:10.1111/dth.14660 | <https://pubmed.ncbi.nlm.nih.gov/33301216/> |
| Gelfand J, Armstrong A, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. *J Am Acad Dermatol*. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058 | <https://pubmed.ncbi.nlm.nih.gov/33422626/> |
| Ghoreschi K, Balato A, Enerback C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. *Lancet*. 2021;397(10275):754-766. doi:10.1016/S0140-6736(21)00184-7 | <https://pubmed.ncbi.nlm.nih.gov/33515492/> |
| Hawkes J, Yan B, Chan T, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. *J Immunol*. 2018;201(6):1605-1613. doi:10.4049/jimmunol.1800013 | <https://pubmed.ncbi.nlm.nih.gov/30181299/> |
| Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities? *J Invest Dermatol*. 2017;137(8):1612-1613. doi:10.1016/j.jid.2017.06.001 | <https://pubmed.ncbi.nlm.nih.gov/28735613/> |
| Boutet M, Nerviani A, Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of Its divergence in skin and joints. *Int J Mol Sci*. 2018;19(2):530. doi:10.3390/ijms19020530 | <https://pubmed.ncbi.nlm.nih.gov/29425183/> |
| Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. *J Dermatol*. 2018;45(3):264-272. doi:10.1111/1346-8138.14139 | <https://pubmed.ncbi.nlm.nih.gov/29226422/> |
| Raharja A, Mahil SK, Barker JN. Psoriasis: A brief overview. *Clin Med (Lond)*. 2021;21(3):170-173. doi:10.7861/clinmed.2021-0257 | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140694/> |
| Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. *Curr Pharm Biotechnol*. 2021;22(1):7-31. doi:10.2174/1389201021666200629150231 | <https://pubmed.ncbi.nlm.nih.gov/32598253/> |
| Sangha AM. Special considerations in the diagnosis and treatment of psoriasis. *J Clin Aesthet Dermatol*. 2021;14(12 suppl 1):S24-S25. | <https://pubmed.ncbi.nlm.nih.gov/35291258/> |
| Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. *Cochrane Database Syst Rev*. 2020;1(1):CD011535. doi:10.1002/14651858.CD011535.pub3 | <https://pubmed.ncbi.nlm.nih.gov/31917873/> |
| Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. *J Am Acad Dermatol.* 2014;71(4):633-641. doi:10.1016/j.jaad.2014.05.001 | <https://pubmed.ncbi.nlm.nih.gov/24928705/> |
| Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. *J Am Acad Dermatol*. 2017;76(3):393-403. doi:10.1016/j.jaad.2016.07.065 | <https://pubmed.ncbi.nlm.nih.gov/28212760/> |
| Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. *Int J Mol Sci*. 2020;21(20):7488. doi:10.3390/ijms21207488 | <https://pubmed.ncbi.nlm.nih.gov/33050592/> |
| Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review. *Am J Clin Dermatol*. 2021;22(2):173-192. doi:10.1007/s40257-020-00578-0 | <https://pubmed.ncbi.nlm.nih.gov/33301128/> |

**Psoriasis Associations and Foundations**

|  |  |
| --- | --- |
| Resource | Address |
| American Academy of Dermatology Association | <https://www.aad.org/> |
| American Dermatological Association | <https://ada1.org/> |
| Centers for Disease Control and Prevention. Psoriasis. | <https://www.cdc.gov/psoriasis/index.htm> |
| National Psoriasis Foundation | <https://www.psoriasis.org/> |
| World Health Organization. Global report on Psoriasis. 2016. | <https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1> |